blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0871494

EP0871494 - COMPOSITIONS AND METHODS FOR TREATING TUMOR CELLS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  26.11.2010
Database last updated on 13.09.2024
Most recent event   Tooltip26.11.2010Application deemed to be withdrawnpublished on 29.12.2010  [2010/52]
Applicant(s)For all designated states
GENTA INCORPORATED
3550 General Atomics Court San Diego
California 92121 / US
For all designated states
Morrison, Richard S.
19125 N.E. 51st Street
Redmond, WA 98053 / US
[N/P]
Former [1998/43]For all designated states
GENTA INCORPORATED
3550 General Atomics Court
San Diego, California 92121 / US
For all designated states
Morrison, Richard S.
19125 N.E. 51st Street
Redmond, WA 98053 / US
Inventor(s)01 / MORRISON, Richard S.
19125 N.E. 51st Street
Redmond, WA 98053 / US
02 / TSENG, Ben Y.
13255 Capstone Drive
San Diego, CA 92130 / US
03 / BROWN, Bob D.
445 N. Willow Spring Drive
Encinitas, CA 92024 / US
[1998/43]
Representative(s)Viering, Jentschura & Partner mbB Patent- und Rechtsanwälte
Grillparzerstrasse 14
81675 München / DE
[N/P]
Former [1998/43]Viering, Jentschura & Partner
Postfach 22 14 43
80504 München / DE
Application number, filing date96902124.511.01.1996
[1998/43]
WO1996US00331
Priority number, dateUS1995037100110.01.1995         Original published format: US 371001
[1998/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9621471
Date:18.07.1996
Language:EN
[1996/33]
Type: A1 Application with search report 
No.:EP0871494
Date:21.10.1998
Language:EN
The application published by WIPO in one of the EPO official languages on 18.07.1996 takes the place of the publication of the European patent application.
[1998/43]
Search report(s)International search report - published on:US18.07.1996
(Supplementary) European search report - dispatched on:EP22.09.2004
ClassificationIPC:A61K48/00, C12N15/11
[2004/25]
CPC:
C12N15/1138 (EP,US); A61P35/00 (EP); A61K38/00 (EP,US);
C12N2310/111 (EP,US); C12N2310/315 (EP,US)
Former IPC [1998/43]A61K48/00
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [1998/43]
TitleGerman:ZUSAMMENSETZUNGEN UND METHODEN ZUR BEHANDLUNG VON TUMORZELLEN[1998/43]
English:COMPOSITIONS AND METHODS FOR TREATING TUMOR CELLS[1998/43]
French:COMPOSITIONS ET METHODES POUR LE TRAITEMENT DES CELLULES TUMORALES[1998/43]
Entry into regional phase08.08.1997National basic fee paid 
08.08.1997Search fee paid 
08.08.1997Designation fee(s) paid 
08.08.1997Examination fee paid 
Examination procedure07.08.1996Request for preliminary examination filed
International Preliminary Examining Authority: US
08.08.1997Examination requested  [1998/43]
20.05.2005Despatch of a communication from the examining division (Time limit: M06)
21.11.2005Reply to a communication from the examining division
07.12.2005Despatch of a communication from the examining division (Time limit: M06)
31.05.2006Reply to a communication from the examining division
12.06.2007Despatch of a communication from the examining division (Time limit: M04)
12.10.2007Reply to a communication from the examining division
02.06.2008Despatch of a communication from the examining division (Time limit: M04)
02.10.2008Reply to a communication from the examining division
17.07.2009Despatch of a communication from the examining division (Time limit: M04)
29.09.2009Reply to a communication from the examining division
19.02.2010Communication of intention to grant the patent
30.06.2010Application deemed to be withdrawn, date of legal effect  [2010/52]
05.08.2010Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2010/52]
Fees paidRenewal fee
12.01.1998Renewal fee patent year 03
30.07.1999Renewal fee patent year 04
27.07.2000Renewal fee patent year 05
25.01.2001Renewal fee patent year 06
28.01.2002Renewal fee patent year 07
28.01.2003Renewal fee patent year 08
14.01.2004Renewal fee patent year 09
26.01.2005Renewal fee patent year 10
12.01.2006Renewal fee patent year 11
12.01.2007Renewal fee patent year 12
14.01.2008Renewal fee patent year 13
14.01.2009Renewal fee patent year 14
Penalty fee
Additional fee for renewal fee
31.01.199904   M06   Fee paid on   30.07.1999
31.01.200005   M06   Fee paid on   27.07.2000
31.01.201015   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO9415945  (TEXAS BIOTECHNOLOGY CORP [US]) [X] 1,2,5-8,16 * page 8 - page 11 * * claim - * [Y] 1,2,5-8,16,17,19-22,27,28;
 [DXY]  - MORRISON RICHARD S ET AL, "Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme", CANCER RESEARCH, (1994), vol. 54, no. 10, ISSN 0008-5472, pages 2794 - 2799, XP001189418 [DX] 1,20,27,28 * abstract * * page 2798, column R * [Y] 1,2,5-8,16,17,19-22,27,28
 [DX]  - BECKER DOROTHEA ET AL, "Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation", ONCOGENE, (1992), vol. 7, no. 11, ISSN 0950-9232, pages 2303 - 2313, XP008030210 [DX] 1,2,5,6,8,16,20-22 * the whole document *
 [DA]  - YAMAGUCHI F ET AL, "Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, (199401), vol. 91, ISSN 0027-8424, pages 484 - 488, XP002141422

DOI:   http://dx.doi.org/10.1073/pnas.91.2.484
International search[Y]WO9500528  (PHARMAGENICS INC [US])
 [Y]  - JOURNAL OF CELLULAR BIOCHEMISTRY, Supplement 0, Volume 18, Part A, issued January 1994, NOBLE, "Steps on the Path to Precursor Cell transplantation for Tissue Repair", page 219, Abstract DZ018.
 [Y]  - JOURNAL OF CELLULAR BIOCHEMISTRY, Supplement O, Volume 17E, MORISHITA et al., "Enhanced Effectiveness of Antisense Oligonucleotides in Vascular Smooth Muscle Cells (VSMC) by HVJ Mediated Gene Transfer", page 239, Abstract SZ318.
 [Y]  - THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 266, Number 2, issued 15 January 1991, MORRISON, "Suppression of Basic Fibroblast Growth Factor Expression by Antisense Oligodeoxynucleotides Inhibits the Growth of Transformed Human Astrocytes", pages 728-734.
 [Y]  - CANCER RESEARCH, Volume 50, issued 15 April 1990, MORRISON et al., "Basic Fibroblast Growth Factor-Like Activity and Receptors are Expressed in a Human Glioma Cell Line", pages 2524-2529.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.